These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 6502472)

  • 61. Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum.
    Kuhnz W; Baumann A; Staks T; Dibbelt L; Knuppen R; Jütting G
    Contraception; 1993 Oct; 48(4):303-22. PubMed ID: 8222659
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Atenolol inhibits the elimination of disopyramide.
    Bonde J; Bødtker S; Angelo HR; Svendsen TL; Kampmann JP
    Eur J Clin Pharmacol; 1985; 28(1):41-3. PubMed ID: 3987784
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Differences between blacks and whites in plasma protein binding of drugs.
    Johnson JA; Livingston TN
    Eur J Clin Pharmacol; 1997; 51(6):485-8. PubMed ID: 9112064
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Plasma binding of disopyramide and mono-N-dealkyldisopyramide.
    Bredesen JE; Pike E; Lunde PK
    Br J Clin Pharmacol; 1982 Nov; 14(5):673-6. PubMed ID: 7138747
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Clinical pharmacokinetics in heart failure. An updated review.
    Shammas FV; Dickstein K
    Clin Pharmacokinet; 1988 Aug; 15(2):94-113. PubMed ID: 3064953
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Protein binding of disopyramide--displacement by mono-N-dealkyldisopyramide and variation with source of alpha-1-acid glycoprotein.
    Haughey DB; Steinberg I; Lee MH
    J Pharm Pharmacol; 1985 Apr; 37(4):285-8. PubMed ID: 2860235
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum.
    Kuhnz W; Staks T; Jütting G
    Contraception; 1994 Dec; 50(6):563-79. PubMed ID: 7705098
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Alpha-1-acid glycoprotein concentration and the protein binding of disopyramide in healthy subjects.
    Kishino S; Nomura A; Di ZS; Sugawara M; Iseki K; Kakinoki S; Kitabatake A; Miyazaki K
    J Clin Pharmacol; 1995 May; 35(5):510-4. PubMed ID: 7657852
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Bioavailability assessment of disopyramide using pharmacokinetic-pharmacodynamic (PK-PD) modeling in the rat.
    Miyazaki M; Maekawa C; Iwanaga K; Morimoto K; Kakemi M
    Biol Pharm Bull; 2000 Nov; 23(11):1363-9. PubMed ID: 11085367
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Influence of serum protein binding on hepatic clearance of S-disopyramide in the rabbit.
    Huang JD; Oie S
    J Pharm Pharmacol; 1985 Jul; 37(7):471-5. PubMed ID: 2863349
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Prolonged variability in plasma protein binding of disopyramide after acute myocardial infarction.
    David BM; Ilett KF; Whitford EG; Stenhouse NS
    Br J Clin Pharmacol; 1983 Apr; 15(4):435-41. PubMed ID: 6849779
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A simple method for the simulation of unbound serum disopyramide concentration in patients.
    Kishino S; Kohri N; Iseki K; Miyazaki K; Nomura A; Yasuda H
    J Pharmacobiodyn; 1991 Sep; 14(9):493-9. PubMed ID: 1779403
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparative bioavailability of disopyramide after multiple dosing with standard capsules and controlled-release tablets.
    Forssell G; Graffner C; Nordlander R; Nyquist O
    Eur J Clin Pharmacol; 1980; 17(3):209-13. PubMed ID: 7363933
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Nomogram for estimating plasma unbound disopyramide concentrations in patients with varying plasma alpha 1-acid glycoprotein concentrations.
    Echizen H; Ishikawa S; Koike K; Ishizaki T
    Ther Drug Monit; 1995 Apr; 17(2):145-52. PubMed ID: 7624903
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Disopyramide concentrations in saliva.
    Aitio ML; Virtanen R; Lammintausta R
    Int J Clin Pharmacol Ther Toxicol; 1982 Feb; 20(2):68-72. PubMed ID: 7061181
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Relationship between alpha 1-acid glycoprotein and distribution of disopyramide and mono-N-dealkyldisopyramide in whole blood.
    Bredesen JE; Kierulf P
    Br J Clin Pharmacol; 1986 Sep; 22(3):281-6. PubMed ID: 3768240
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Population pharmacokinetics of total and unbound etoposide.
    Nguyen L; Chatelut E; Chevreau C; Tranchand B; Lochon I; Bachaud JM; Pujol A; Houin G; Bugat R; Canal P
    Cancer Chemother Pharmacol; 1998; 41(2):125-32. PubMed ID: 9443625
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Altered plasma protein-binding of prednisolone in patients with the nephrotic syndrome.
    Frey FJ; Frey BM
    Am J Kidney Dis; 1984 Mar; 3(5):339-48. PubMed ID: 6702820
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Comparison of electrocardiographic response and disposition of R- and S-disopyramide in the rabbit.
    Huang JD; Oie S
    Res Commun Chem Pathol Pharmacol; 1983 Aug; 41(2):227-41. PubMed ID: 6635318
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The influence of blood collection technique on serum and plasma protein binding of disopyramide.
    Haughey DB; Lima JJ
    Eur J Clin Pharmacol; 1982; 22(2):185-9. PubMed ID: 7094989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.